Literature DB >> 7389584

Teratogenic activity in the mouse after oral administration of acetazolamide.

C I Tellone, J K Baldwin, R D Sofia.   

Abstract

Acetazolamide was administered orally by gavage to pregnant mice twice a day on days six through 15 of gestation at a dose level of 300.0 mg/kg. This treatment produced maternal toxicity as evidenced by significantly reduced food consumption and body weight gain. Embryotoxicity demonstrated by significant reductions in fetal weight and crown-rump length was also observed. Resorption rates were considerably higher (77.9%) for the acetazolamide treated litters when compared to those from the control group (8.23%). A variety of malformations was observed in the acetazolamice-treated rats (rib and vertebral fusion, gastroschisis, tail defects, cleft palate and ectrodactyly). These results further establish acetazolamide as an acceptable positive teratogenic control by demonstration of species and strain susceptibility in the CD-1 mouse.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7389584     DOI: 10.3109/01480548009017835

Source DB:  PubMed          Journal:  Drug Chem Toxicol        ISSN: 0148-0545            Impact factor:   3.356


  4 in total

Review 1.  Animal models in pediatric surgery.

Authors:  A Mortell; S Montedonico; P Puri
Journal:  Pediatr Surg Int       Date:  2005-12-06       Impact factor: 1.827

Review 2.  Teratogens inducing congenital abdominal wall defects in animal models.

Authors:  Dennis R Van Dorp; John M Malleis; Brian P Sullivan; Michael D Klein
Journal:  Pediatr Surg Int       Date:  2009-09-16       Impact factor: 1.827

3.  Embryotoxicity induced by alkylating agents: left-sided preponderance of paw malformations induced by acetoxymethyl-methylnitrosamine in mice.

Authors:  G Bochert; T Platzek; G Blankenburg; M Wiessler; D Neubert
Journal:  Arch Toxicol       Date:  1985-01       Impact factor: 5.153

4.  Possible association between acetazolamide administration during pregnancy and multiple congenital malformations.

Authors:  Afnan I Al-Saleem; Asma M Al-Jobair
Journal:  Drug Des Devel Ther       Date:  2016-04-15       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.